These screens, unexpectedly, revealed the potential therapeutic utility of targeting the cullin4-RING E3 ubiquitin ligase (CRL4) substrate adaptor DCAF15 in myeloid malignancies. The gene discussed is DCAF15; the disease is myeloid neoplasm.